Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Metabolism-Related Features Identify the Combination Metformin Plus NAMPT Inhibitors As a Selective Treatment Strategy in Acute Myeloid Leukemia

Isabel Weinhaeuser, Diego Pereira-Martins, Dominique Sternadt, Emmanuel F Griessinger, Douglas RA Silveira, Juan L Coelho-Silva, Antonio Bruno Alves-Silva, Ayşegül Erdem, Bruno Koza Lino Duarte, Lynn Quek, Fabiola Traina, Sara Teresinha Olalla Saad, Jacobien R Hilberink, Emanuele Ammatuna, Eduardo Magalhães Rego, Geert A. Huls, Antonio R Lucena-Araujo, Jan Jacob Schuringa

Blood (2023) 142 (Supplement 1): 294.

https://doi.org/10.1182/blood-2023-186061

Published: 2023

Journal Articles

An Integrated Single Cell Immunogenomic Atlas Reveals Pathways of Clonal Expansion, Inflammation and Dyserythropoiesis in Low and High-Risk Clonal Haematopoiesis

Xuesen Zheng, Amandine Tan, Maria del Pilar Casares Alaez, Garry Mallett, Deniz Ece Kaya, Nogayhan Seymen, Marta Rzepkowska, Sarah Mackie, Prodromos Chatzikyriakou, Laarni Bogaanay, Jen Lewis, Maroof Hasan, Rajasekhar N.V.S. Suragani, James Carmichael, Ghulam Mufti, Anita K. Gandhi, Giorgio Napolitani, Lynn Quek

Blood (2023) 142 (Supplement 1): 812.

https://doi.org/10.1182/blood-2023-174947

Published: 2023

Journal Articles

Metformin-Induced Ferroptosis Is a Therapeutic Vulnerability in IDH2 -Mutant AML Linked to Metabolic Rewiring Towards Fatty Acid Oxidation

Dominique Sternadt, Diego Pereira-Martins, Douglas RA Silveira, Isabel Weinhaeuser, Ming Yang, Prodromos Chatzikyriakou, Pilar Casares Alaez, Emanuele Ammatuna, Lieve Oudejans, Gerwin A. Huls, Christian Frezza, Lynn Quek, Jan Jacob Schuringa

Blood (2023) 142 (Supplement 1): 1586.

https://doi.org/10.1182/blood-2023-188524

Published: 2023

Journal Articles

CEBPA-Driven Expression of the Transcriptionally Inactive deltaTP73 Isoform Phenocopies TP53 mutated Poor Risk and Drug-Resistant Acute Myeloid Leukemia

Diego Pereira-Martins, César Alexander Ortiz Rojas, Isabel Weinhaeuser, Bart-Jan Wierenga, Vincent Van Den Boom, Fatemeh Mojallali, Dominique Sternadt, Thiago Mantello Bianco, Nisha van der Meer, Douglas RA Silveira, Lynn Quek, Emanuele Ammatuna, Antonio R Lucena-Araujo, Gerwin A. Huls, Eduardo Magalhães Rego, Jan Jacob Schuringa

Blood (2023) 142 (Supplement 1): 839.

https://doi.org/10.1182/blood-2023-186399

Published: 2023

Journal Articles

Single Cell Characterisation of Transcriptional Programmes of Responsive and Resistant Leukaemic Progenitors in IDH2 -Mutant Acute Myeloid Leukaemia in the AG221-AML-005 Study

Prodromos Chatzikyriakou, Douglas RA Silveira, Maria del Pilar Casares Aláez, Batchimeg Usukhbayar, Marlen Metzner, Paresh Vyas, Anita K. Gandhi, Alberto Risueño, Maroof Hasan, Lynn Quek

Blood (2022) 140 (Supplement 1): 3414–3415.

https://doi.org/10.1182/blood-2022-163717

Published: 2022

Journal Articles

Single-Cell Transcriptome Analysis Reveals Pathways That Drive Dyserythropoiesis in Myelodysplastic Syndromes, Which Are Targeted By Luspatercept

Onima Chowdhury, Douglas RA Silveira, Sophie Reed, Jennifer O'Sullivan, Sally-Ann Clark, Neil Ashley, Bethan Psaila, Supat Thongjuea, Adam J Mead, Lynn Quek

Blood (2022) 140 (Supplement 1): 9753–9754.

https://doi.org/10.1182/blood-2022-165865

Published: 2022

Journal Articles

High MN1 Expression Is Associated with an Lspc-Enriched Phenotype and Glycolysis Representing a New Vulnerability in Acute Myeloid Leukemia

Diego Pereira-Martins, Noortje van Dijk, Isabel Weinhaeuser, Douglas RA Silveira, Juan Coelho Da Silva, Thiago M Bianco, César Alexander Ortiz, Fabiola Traina, Lorena L Figueiredo-Pontes, Emanuele Ammatuna, Lynn Quek, Gerwin A. Huls, Antonio R. Lucena-Araujo, Eduardo M Rego, Jan Jacob Schuringa

Blood (2022) 140 (Supplement 1): 6265–6266.

https://doi.org/10.1182/blood-2022-165151

Published: 2022

Journal Articles

Impaired Metabolic Plasticity Under Stress Constitutes a Therapeutic Vulnerability in IDH1/2 -Mutant Acute Myeloid Leukemia

Dominique Sternadt, Diego Pereira-Martins, Douglas RA Silveira, Prodromos Chatzikyriakou, Maria del Pilar Casares Alaez, Isabel Weinhaeuser, Shanna M Hogeling, Emanuele Ammatuna, Gerwin A. Huls, Lynn Quek, Jan Jacob Schuringa

Blood (2022) 140 (Supplement 1): 8813–8814.

https://doi.org/10.1182/blood-2022-163282

Published: 2022

Journal Articles

M2 Macrophages Drive Resistance to Phagocytosis and Improve Mitochondrial Metabolism in Acute Myeloid Leukemia Facilitating Leukemic Transformation and In Vivo Engraftment

Isabel Weinhaeuser, Diego Pereira-Martins, Luciana Yamamoto de Almeida, Jacobien R Hilberink, Douglas RA Silveira, Lynn Quek, César Alexander Ortiz, Antonio R. Lucena-Araujo, Nienke Visser, Emanuele Ammatuna, Gerwin A. Huls, Eduardo M Rego, Jan Jacob Schuringa

Blood (2022) 140 (Supplement 1): 1259–1260.

https://doi.org/10.1182/blood-2022-165130

Published: 2022

Journal Articles

Dysregulation of Stem-Progenitor and Differentiation Programmes through Modulation of Bivalent Chromatin Drives Leukemogenesis in Mutant IDH2 Acute Myeloid Leukaemia

Douglas RA RA Silveira, Prodromos Chatzikyriakou, Maria del Pilar Casares Alaez, Sarah Mackie, Roan Hulks, Olena Yavorska, Paulina Siejka-Zielinska, Marlen Metzner, Alastair Smith, Batchimeg Usukhbayar, Virginie Penard-Lacronique, Chunxiao Song, Anita K. Gandhi, Maroof Hasan, Paresh Vyas, Thomas A. Milne, Skirmantas Kriaucionis, Lynn Quek

Blood (2022) 140 (Supplement 1): 8698–8699.

https://doi.org/10.1182/blood-2022-165898

Published: 2022

Journal Articles

Molecular Features Associated with Response to Combination Therapy with Enasidenib (ENA) Plus Azacitidine (AZA) in Newly Diagnosed IDH2 -Mutated Acute Myeloid Leukemia (AML)

Alberto Risueño, Wendy L. See, Courtney D. DiNardo, Hartmut Döhner, Eytan Stein, Amir T. Fathi, Paresh Vyas, Lynn Quek, Thomas Prebet, Anita K. Gandhi, Maroof Hasan

Blood (2022) 140 (Supplement 1): 732–734.

https://doi.org/10.1182/blood-2022-158967

Published: 2022

Journal Articles

Tumor Associated Macrophages Promoted Fatal Patient Derived Acute Promyelocytic Leukemia In Vivo

Isabel Weinhäuser, Diego A Pereira-Martins, Jacobien R Hilberink, Luciana Yamamoto Almeida, Douglas RA Silveira, Lynn Quek, Shanna M Hogeling, Jose Mauricio Mota, Emanuele Ammatuna, Antonio R. Lucena-Araujo, Gerwin A. Huls, Jan Jacob Schuringa, Eduardo M Rego

Blood (2021) 138 (Supplement 1): 3472.

https://doi.org/10.1182/blood-2021-150699

Published: 2021

Journal Articles

Repressed Chromatin Drives Leukaemogenesis in Mutant IDH2 Acute Myeloid Leukaemia Via Inhibition of Granulocyte Differentiation and Cell Cycle Progression

Douglas RA Silveira, Prodromos Chatzikyriakou, Olena Yavorska, Sarah Mackie, Roan Hulks, Paulina Siejka-Zielinska, Anna Corby, Alastair Smith, Benjamin Brown, Marlen Metzner, Thomas A. Milne, Virginie Penard-Lacronique, Chunxiao Song, Maroof Hasan, Anjan Thakurta, Paresh Vyas, Skirmantas Kriaucionis, Lynn Quek

Blood (2021) 138 (Supplement 1): 3467.

https://doi.org/10.1182/blood-2021-149519

Published: 2021

Journal Articles

Co-occurrence of DNMT3A , NPM1 , FLT3 mutations identifies a subset of acute myeloid leukemia with adverse prognosis

Blood (2020) 135 (11): 870–875.

https://doi.org/10.1182/blood.2019003339

Published: 2020

Includes: Supplemental data

Journal Articles

Complex Polyclonal Resistance Mechanisms to Ivosidenib Monotherapy in IDH1 -Mutant Relapsed or Refractory Acute Myeloid Leukemia Revealed By Single Cell Sequencing Analyses

Hongfang Wang, PhD, Sung Choe, PhD, Courtney D. DiNardo, MD MSc, Eytan M. Stein, MD, Stéphane de Botton, MD PhD, Amir T. Fathi, MD, Martin S. Tallman, MD, Hagop M. Kantarjian, MD, Richard M. Stone, MD, Lynn Quek, MD PhD, Vickie Zhang, PhD, Hua Liu, PhD, Eyal C. Attar, MD, Bin Wu, PhD

Blood (2019) 134 (Supplement_1): 541.

https://doi.org/10.1182/blood-2019-122703

Published: 2019

Journal Articles

Molecular Mechanisms Mediating Relapse Following Ivosidenib Monotherapy in Patients with IDH1 -Mutant Relapsed or Refractory Acute Myeloid Leukemia

Sung Choe, PhD, Hongfang Wang, PhD, Courtney D. DiNardo, MD MSc, Eytan M. Stein, MD, Stephane De Botton, Amir T. Fathi, MD, Martin S. Tallman, MD, Hagop M. Kantarjian, MD, Richard M. Stone, MD, Lynn Quek, MD PhD, Zenon Konteatis, PhD, Lenny Dang, PhD, Vickie Zhang, PhD, Hua Liu, PhD, Eyal C. Attar, MD, Bin Wu, PhD

Blood (2019) 134 (Supplement_1): 545.

https://doi.org/10.1182/blood-2019-122671

Published: 2019

Journal Articles

Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 ( IDH2 ) Mutations: Interim Phase II Results from an Ongoing, Randomized Study

Courtney D. DiNardo, MD MSc, Andre C. Schuh, MD, Eytan M. Stein, MD, Pau Montesinos Fernandez, MD PhD, Andrew Wei, MBBS, FRACP, FRCPA, PhD, Stephane De Botton, Amer M. Zeidan, MBBS, MHS, Amir T. Fathi, MD, Lynn Quek, MD PhD, Hagop M. Kantarjian, MD, Mark G. Frattini, MD, Frederik Lersch, RN, Jing Gong, PhD, Aleksandra Franovic, PhD, Kyle MacBeth, PhD, Paresh Vyas, MD PhD, Hartmut Döhner, MD

Blood (2019) 134 (Supplement_1): 643.

https://doi.org/10.1182/blood-2019-130362

Published: 2019

Journal Articles

Combining Clinical Features with Genetic Factors Improves Survival Prediction for Adults with Acute Myeloid Leukemia: Validation of a New Score System in 3 Cohorts

Douglas R. A. Silveira, Lynn Quek, MD PhD, Anna Corby, B.Sc., Juan L Coelho-Silva, BSc, MSc, Diego A Pereira-Martins, MSc, Grant Vallance, B.Sc., PhD, Benjamin Brown, B.Sc., PhD, Luciana Nardinelli, M.Sc, Wellington F Silva, MD, Elvira DRP Velloso, MD PhD, Fabiola Traina, MD PhD, Andy Peniket, MD, Paresh Vyas, MD PhD, Eduardo M Rego, MD PhD, Israel Bendit, MD PhD, Vanderson Rocha, MD PhD

Blood (2019) 134 (Supplement_1): 2602.

https://doi.org/10.1182/blood-2019-130726

Published: 2019

Journal Articles

High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1 -Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib (AG-120) and Azacitidine

Scott R. Daigle, MS, Sung Choe, PhD, Lynn Quek, MD PhD, Courtney D. DiNardo, MDMSc, Anthony Stein, MD, Eytan M. Stein, MD, Amir T. Fathi, MD, Olga Frankfurt, MD, Andre C. Schuh, MD, Hagop M. Kantarjian, MD, Vickie Zhang, PhD, Thomas Winkler, MD, Paresh Vyas, MD PhD, Bin Wu, PhD

Blood (2019) 134 (Supplement_1): 2706.

https://doi.org/10.1182/blood-2019-122590

Published: 2019

Journal Articles

Therapy-Related Myeloid Neoplasms with Balanced Chromosome Rearrangements Frequently Arise from Pre-Existing Clonal Haematopoiesis

Richard Dillon, MA, PhD MRCP, FRCPath, Jelena Jovanovic, PhD, Nicola Potter, PhD, Nicola Foot, MSc, Matthew J Ahearne, MD MBBS, Sandrine Jayne, PhD, Michael Dennis, MD MRCP, FRCPath, Ann E. Hunter, MBBS, FRCP, FRCPath, Martin J.S. Dyer, Paresh Vyas, Lynn Quek, FRCPath, DPhil, MBBS, Nigel H. Russell, Robert K. Hills, MA, DPhil, MSc, Ellen Solomon, PhD, David Grimwade, PhD MRCP, MRCPath

Blood (2018) 132 (Supplement 1): 2570.

https://doi.org/10.1182/blood-2018-99-114233

Published: 2018

NARROW

Metabolism-Related Features Identify the Combination Metformin Plus NAMPT Inhibitors As a Selective Treatment Strategy in Acute Myeloid Leukemia

An Integrated Single Cell Immunogenomic Atlas Reveals Pathways of Clonal Expansion, Inflammation and Dyserythropoiesis in Low and High-Risk Clonal Haematopoiesis

Metformin-Induced Ferroptosis Is a Therapeutic Vulnerability in IDH2 -Mutant AML Linked to Metabolic Rewiring Towards Fatty Acid Oxidation

CEBPA-Driven Expression of the Transcriptionally Inactive deltaTP73 Isoform Phenocopies TP53 mutated Poor Risk and Drug-Resistant Acute Myeloid Leukemia

Single Cell Characterisation of Transcriptional Programmes of Responsive and Resistant Leukaemic Progenitors in IDH2 -Mutant Acute Myeloid Leukaemia in the AG221-AML-005 Study

Single-Cell Transcriptome Analysis Reveals Pathways That Drive Dyserythropoiesis in Myelodysplastic Syndromes, Which Are Targeted By Luspatercept

High MN1 Expression Is Associated with an Lspc-Enriched Phenotype and Glycolysis Representing a New Vulnerability in Acute Myeloid Leukemia

Impaired Metabolic Plasticity Under Stress Constitutes a Therapeutic Vulnerability in IDH1/2 -Mutant Acute Myeloid Leukemia

M2 Macrophages Drive Resistance to Phagocytosis and Improve Mitochondrial Metabolism in Acute Myeloid Leukemia Facilitating Leukemic Transformation and In Vivo Engraftment

Dysregulation of Stem-Progenitor and Differentiation Programmes through Modulation of Bivalent Chromatin Drives Leukemogenesis in Mutant IDH2 Acute Myeloid Leukaemia

Molecular Features Associated with Response to Combination Therapy with Enasidenib (ENA) Plus Azacitidine (AZA) in Newly Diagnosed IDH2 -Mutated Acute Myeloid Leukemia (AML)

Tumor Associated Macrophages Promoted Fatal Patient Derived Acute Promyelocytic Leukemia In Vivo

Repressed Chromatin Drives Leukaemogenesis in Mutant IDH2 Acute Myeloid Leukaemia Via Inhibition of Granulocyte Differentiation and Cell Cycle Progression

Co-occurrence of DNMT3A , NPM1 , FLT3 mutations identifies a subset of acute myeloid leukemia with adverse prognosis

Complex Polyclonal Resistance Mechanisms to Ivosidenib Monotherapy in IDH1 -Mutant Relapsed or Refractory Acute Myeloid Leukemia Revealed By Single Cell Sequencing Analyses

Molecular Mechanisms Mediating Relapse Following Ivosidenib Monotherapy in Patients with IDH1 -Mutant Relapsed or Refractory Acute Myeloid Leukemia

Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 ( IDH2 ) Mutations: Interim Phase II Results from an Ongoing, Randomized Study

Combining Clinical Features with Genetic Factors Improves Survival Prediction for Adults with Acute Myeloid Leukemia: Validation of a New Score System in 3 Cohorts

High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1 -Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib (AG-120) and Azacitidine

Therapy-Related Myeloid Neoplasms with Balanced Chromosome Rearrangements Frequently Arise from Pre-Existing Clonal Haematopoiesis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only